Literature DB >> 19408347

The role of ADAMs in disease pathophysiology.

Michael J Duffy1, Eadaoin McKiernan, Norma O'Donovan, Patricia M McGowan.   

Abstract

The ADAMs are a family of multidomain transmembrane and secreted proteins involved in both proteolysis and cell adhesion. Altered expression of specific ADAMs is implicated in the pathophysiology of several diseases including rheumatoid arthritis, Alzheimer's disease, cardiac hypertrophy, asthma and cancer. Of these different diseases, it is in cancer where most research has been carried out. Multiple ADAMs, including ADAM-9, ADAM-10, ADAM-12, ADAM-15 and ADAM-17, have been shown to play a role in either cancer formation or progression. Consistent with these findings, increased expression of specific ADAMs in several cancer types was found to correlate with features of aggressive disease and poor prognosis. Currently, selective ADAM inhibitors against ADAM-10 and ADAM-17 are undergoing clinical trials for the treatment of cancer. Further work is required in order to establish a causative role for ADAMs in rheumatoid arthritis, Alzheimer's disease, cardiac hypertrophy and asthma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19408347     DOI: 10.1016/j.cca.2009.01.007

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  20 in total

1.  Differentiation of prostate cancer cells using flexible fluorescent polymers.

Authors:  Michael D Scott; Rinku Dutta; Manas K Haldar; Bin Guo; Daniel L Friesner; Sanku Mallik
Journal:  Anal Chem       Date:  2011-12-14       Impact factor: 6.986

Review 2.  Physiological functions of the amyloid precursor protein secretases ADAM10, BACE1, and presenilin.

Authors:  Johannes Prox; Andrea Rittger; Paul Saftig
Journal:  Exp Brain Res       Date:  2011-11-27       Impact factor: 1.972

3.  High-throughput protease activity cytometry reveals dose-dependent heterogeneity in PMA-mediated ADAM17 activation.

Authors:  Lidan Wu; Allison M Claas; Aniruddh Sarkar; Douglas A Lauffenburger; Jongyoon Han
Journal:  Integr Biol (Camb)       Date:  2015-04-02       Impact factor: 2.192

4.  Degradome of soluble ADAM10 and ADAM17 metalloproteases.

Authors:  Franka Scharfenberg; Andreas Helbig; Martin Sammel; Julia Benzel; Uwe Schlomann; Florian Peters; Rielana Wichert; Maximilian Bettendorff; Dirk Schmidt-Arras; Stefan Rose-John; Catherine Moali; Stefan F Lichtenthaler; Claus U Pietrzik; Jörg W Bartsch; Andreas Tholey; Christoph Becker-Pauly
Journal:  Cell Mol Life Sci       Date:  2019-06-17       Impact factor: 9.261

5.  Tetraspanin15 regulates cellular trafficking and activity of the ectodomain sheddase ADAM10.

Authors:  Johannes Prox; Michael Willenbrock; Silvio Weber; Tobias Lehmann; Dirk Schmidt-Arras; Ralf Schwanbeck; Paul Saftig; Michael Schwake
Journal:  Cell Mol Life Sci       Date:  2012-03-25       Impact factor: 9.261

6.  Prognostic value of ADAM17 in human gastric cancer.

Authors:  Tie-cheng Zhang; Wei-guo Zhu; Ming-de Huang; Rui-hua Fan; Xiao-fei Chen
Journal:  Med Oncol       Date:  2011-12-03       Impact factor: 3.064

7.  ADAM10 and ADAM17: New players in trastuzumab tesistance.

Authors:  Michael J Duffy; John Crown; Maeve Mullooly
Journal:  Oncotarget       Date:  2014-11-30

8.  ADAM17 is overexpressed in non-small cell lung cancer and its expression correlates with poor patient survival.

Authors:  Shuang-Shuang Ni; Ji Zhang; Wei-Li Zhao; Xiao-Chun Dong; Jin-Lin Wang
Journal:  Tumour Biol       Date:  2013-03-09

Review 9.  A disintegrin and metalloproteinase-12 (ADAM12): function, roles in disease progression, and clinical implications.

Authors:  Erin K Nyren-Erickson; Justin M Jones; D K Srivastava; Sanku Mallik
Journal:  Biochim Biophys Acta       Date:  2013-05-13

Review 10.  The ADAMs family of proteases as targets for the treatment of cancer.

Authors:  Maeve Mullooly; Patricia M McGowan; John Crown; Michael J Duffy
Journal:  Cancer Biol Ther       Date:  2016-04-26       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.